Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

International Myeloma Workshop highlights and ongoing IMF studies

IMW 2011

Published: 20 May 2011

Views: 6258

Rating:

Save

Prof Thierry Facon - Centre Hospitalier Universitaire, Lille, France

Prof Facon discusses an ongoing study of melphalan-prednisone-thalidomide (MP-T) vs low dose lenalidomide-dexamethasone for 18 cycles or until progressive myeloma. The study includes 1623 patients across 300 centres in various countries and is likely to report in 2012. He also discusses some highlights of the International Myeloma Workshop, Paris, 5th May 2011.

Related Videos

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients

Dr Prashant Mehta - Amrita Hospital, Karala, India

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients ( Dr Prashant Mehta - Amrita Hospital, Karala, India )

Multiple Myeloma: evolving paradigm - Panel Discussion

Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr...

Multiple Myeloma: evolving paradigm - Panel Discussion ( Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar )

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India

Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India

Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

ATRA-ATO regimen with idarubicin could become the new standard of care in high...

Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia ( Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany )

Ponatinib is better than imatinib for frontline treatment of newly diagnosed...

Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia ( Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

More from ecancer